gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · LGNDHealthcarePharmaceuticals

Ligand Pharmaceuticals Inc. (LGND)

$316.13+0.83%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$314.41▲ 64.41% in range
Nov 3, 2025Low $181.65 · High $322.75Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ligand Pharmaceuticals closed at $316.13 on Nov 4, up 0.83%, 2.1% below its 52-week closing high. Volume of 180.0K shares was 0.74× its 20-day average (below normal).

Split-adjusted performance: +6.5% over one month, +35.9% over six months, +65.3% over one year.

In the quarter ended Sep 30, 2026, revenue was $78.75M, down 31.8% from a year earlier, with a net margin of -36.2%.

Short interest was 2.5M shares at the Oct 15 settlement, down 6.6% from the prior report (13.3% of float, 10.5 days to cover).

Market cap$6.32B20.0M shares
Revenue · quarter$78.7M−31.8% YoY
Diluted EPS$-1.43−125.2% YoY
P/E · TTM122.9×P/S 24.9×
Net margin-36.2%Gross 83.7%
Dividend yieldNone$0.0763 last paid
52-week range181.65 – 322.75−2.1% from high
Volume180.0K0.74× 20-day avg
Volatility · 60d29.3%Annualised
Short % of float13.3%10.5 days to cover
Net cash-$653.3MCash $474.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.8%1M +6.5%3M +5.3%6M +35.9%YTD +67.2%1Y +65.3%3Y +521.4%5Y +127.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum89
Revenue growth26
Net margin49
Value (low P/E)5
Size91

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.5M−6.6% vs prior
Days to cover10.5Settled Oct 15
% of float13.3%
Short vol. 10d68.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
LGNDLigand Pharmaceuticals$316.13+0.83%+35.9%−31.8%−36.2%122.9$6.32B
MIRMMirum Pharmaceuticals$96.97+11.42%−11.9%+39.6%−22.0%—$6.30BCompare
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67BCompare
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
PTCTPTC Therapeutics$68.97+1.25%+3.6%+69.6%−14.4%—$5.76BCompare
AMRXAmneal Pharmaceuticals$19.95−1.29%+46.5%+9.9%7.2%44.2$6.95BCompare
MANEVeradermics, Incorporated$136.51+2.17%+24.4%———$5.70BCompare
AXSMAxsome Therapeutics$137.00−1.87%−38.5%+51.9%−5.0%—$7.18BCompare
COGTCogent Biosciences$31.49+1.38%−12.2%———$5.46BCompare

News about Ligand Pharmaceuticals

All news →
Ligand to Participate in September Investor ConferencesGlobeNewswire Inc. · Aug 26, 2026NeutralLigand Announces 2026 Investor Day in New York CityGlobeNewswire Inc. · Jun 10, 2026▲ PositiveA Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 MillionThe Motley Fool · Jun 7, 2026▲ PositiveLigand Bets On Royalty Growth With XOMA Buyout Worth Over $700 MillionBenzinga · Apr 27, 2026▲ PositiveLigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorBenzinga · Apr 27, 2026▲ Positive

Quick answers

What does Ligand Pharmaceuticals do?
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies.
What is LGND's market cap?
$6.32B, based on the Nov 4 close of $316.13.
What is LGND's P/E ratio?
122.9× trailing-twelve-month earnings of $51.46M.
Does Ligand Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of LGND is sold short?
2.5M shares, 13.3% of float, as of Oct 15, 2026.
What sector is LGND in?
Healthcare, in the Pharmaceuticals industry.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

HQ: San Diego, CA47 employeesListed Nov 25, 1994ligand.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology